

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

OPM-2

RRID:CVCL_1625

Type: Cell Line

Proper Citation

RRID:CVCL_1625

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1625

Proper Citation: RRID:CVCL_1625

Description: Cell line OPM-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:3926660](#), [PMID:8943038](#), [PMID:10087940](#), [PMID:10583232](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:15215163](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:20164919](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Produces Ig lambda., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OPM-2

Synonyms: OPM2

Cross References: BTO:BTO_0005919, CLO:CLO_0008269, EFO:EFO_0006716, CLDB:cl3774, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-

MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-937, BioGRID_ORCS_Cell_line:977, BioSample:SAMN03473240, BioSample:SAMN10988562, cancercellines:CVCL_1625, Cell_Model_Passport:SIDM00457, CGH-DB:36-1, CGH-DB:9158-4, ChEMBL-Cells:ChEMBL3308883, ChEMBL-Targets:ChEMBL2366353, Cosmic:720767, Cosmic:735529, Cosmic:759901, Cosmic:759907, Cosmic:760390, Cosmic:760403, Cosmic:909249, Cosmic:1889515, Cosmic:2081432, Cosmic:2302417, Cosmic:2367300, Cosmic:2391792, Cosmic:2809760, Cosmic-CLP:909249, DepMap:ACH-000024, DSMZ:ACC-50, DSMZCellDive:ACC-50, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:909249, GEO:GSM143336, GEO:GSM290303, GEO:GSM562818, GEO:GSM887478, GEO:GSM888559, GEO:GSM1374799, GEO:GSM1670307, IARC_TP53:21603, IARC_TP53:28518, LiGeA:CCLE_834, LINCS_LDP:LCL-2048, PharmacDB:OPM2_1202_2019, PRIDE:PXD030239, PRIDE:PXD030304, Progenetix:CVCL_1625, PubChem_Cell_line:CVCL_1625, Wikidata:Q54936482

ID: CVCL_1625

Record Creation Time: 20220427T221359+0000

Record Last Update: 20260829T235515+0000

Ratings and Alerts

No rating or validation information has been found for OPM-2.

No alerts have been found for OPM-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Jiang K, et al. (2026) The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. Molecular cancer therapeutics, 25(6), 1016.

Burnham CM, et al. (2026) An enhancement of extrachromosomal circular DNA enrichment and amplification to address the extremely low overlap between replicates. *The Journal of biological chemistry*, 302(4), 111302.

Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. *British journal of pharmacology*, 183(12), 3355.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. *Nature communications*, 16(1), 7793.

Cardona-Benavides IJ, et al. (2025) Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. *Molecular oncology*.

Tran S, et al. (2025) Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. *Blood neoplasia*, 2(1), 100050.

Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. *Cell reports. Medicine*, 6(10), 102400.

Burnham CM, et al. (2025) An Enhancement of Extrachromosomal Circular DNA Enrichment and Amplification to Address the Extremely Low Overlap Between Replicates. *bioRxiv : the preprint server for biology*.

Oudaert I, et al. (2025) PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism. *Molecular oncology*.

Murphy CS, et al. (2025) Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. *Molecular oncology*, 19(6), 1687.

Ticona-Pérez FV, et al. (2024) Multiple mechanisms contribute to acquired TRAIL resistance in multiple myeloma. *Cancer cell international*, 24(1), 275.

Costacurta M, et al. (2024) Mapping the IMiD-dependent cereblon interactome using BioID-proximity labelling. *The FEBS journal*.

Singh RK, et al. (2024) Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models. *Research square*.

Pu J, et al. (2024) Synergistic integration of histone deacetylase inhibitors apparently enhances the cytokine-induced killer cell efficiency in multiple myeloma via the NKG2D pathway. *Clinical & translational immunology*, 13(3), e1500.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. *Cancer cell*, 42(7), 1185.

Nicosia L, et al. (2023) Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies. *Cancer cell*, 41(12), 2136.

Beltrán-Visiedo M, et al. (2023) Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients. *Molecular oncology*, 17(12), 2507.